Back to News
Nov 7, 2025 12:00 PM

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Gilead Sciences Inc. (NASDAQ:GILD) announced on Friday data from the Phase 3 ASCENT-07 study of Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in HR+/HER2-negative metastatic breast cancer patients.

The trial included patients who received prior endocrine therapy and were candidates for cytotoxic chemotherapy.

The study did not meet the primary endpoint of progression-free survival (PFS), the time during and after treatment when a disease, such as cancer, does not get worse.

Overall survival is a key secondary endpoint and was not mature at the time of the primary analysis; however, an early trend favoring Trodelvy over ...